St. Johns Investment Management’s Atossa Therapeutics ATOS Stock Holding History

St. Johns Investment Management’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-103	Closed	-$1.46K	–	199
2024 Q4	$1.46K	Hold	103	–	–	﹤0.01%	182
2024 Q3	$2.36K	Hold	103	–	–	﹤0.01%	184
2024 Q2	$1.84K	Hold	103	–	–	﹤0.01%	165
2024 Q1	$2.79K	Hold	103	–	–	﹤0.01%	166
2023 Q4	$1.36K	Hold	103	–	–	﹤0.01%	165
2023 Q3	$1.14K	Hold	103	–	–	﹤0.01%	165
2023 Q2	$1.95K	Hold	103	–	–	﹤0.01%	166
2023 Q1	$1.12K	Hold	103	–	–	﹤0.01%	158
2022 Q4	$819	Hold	103	–	–	﹤0.01%	156
2022 Q3	$1K	Hold	103	–	–	﹤0.01%	157
2022 Q2	$2K	Hold	103	–	–	﹤0.01%	147
2022 Q1	$2K	Hold	103	–	–	﹤0.01%	160
2021 Q4	$2K	Hold	103	–	–	﹤0.01%	173
2021 Q3	$5K	Hold	103	–	–	﹤0.01%	136
2021 Q2	$10K	Buy	+103	New	+$5.45K	0.01%	120

Other funds holding ATOS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

St. Johns Investment Management's ATOS Position: Q1 2025 in Review

St. Johns Investment Management sold out of Atossa Therapeutics (ATOS) in Q1 2025, closing a stake of 103 shares — an estimated $1.46K sold.

St. Johns Investment Management first reported a position in ATOS in Q2 2021 and held it in 15 quarters. The position peaked at $10K in Q2 2021. 83 funds tracked by Wall St. Rank hold ATOS as of Q1 2025.

St. Johns Investment Management reported no remaining Atossa Therapeutics position as of Q1 2025 after selling out during the quarter.
St. Johns Investment Management sold 103 Atossa Therapeutics shares in Q1 2025, an estimated $1.46K.
St. Johns Investment Management first reported a position in Atossa Therapeutics in Q2 2021 and held it in 15 quarters.
St. Johns Investment Management's Atossa Therapeutics position peaked at $10K in Q2 2021.
83 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2025.

Based on St. Johns Investment Management's 13F filing for Q1 2025, filed 23 Apr 2025.